Cue Biopharma (CUE) Income from Continuing Operations (2017 - 2025)
Cue Biopharma (CUE) posted Income from Continuing Operations of 1962000.0 for Q4 2025, up 123.98% sequentially from 8181000.0 in Q3 2025, and up 121.36% YoY from 886344.64 in Q4 2024.
Cue Biopharma (CUE) Income from Continuing Operations (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Income from Continuing Operations for 9 years, with the latest figure at 1962000.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 121.36% year-over-year to 1962000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 36990000.0 (up 30.6% YoY) and the FY2025 annual result came in at 28040000.0, up 25.69% from the prior year.
- Income from Continuing Operations climbed to 1962000.0 in Q4 2025 per CUE's latest filing, from 8181000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1962000.0 in Q4 2025 and troughed at 18831000.0 in Q1 2021.
- A 5-year average of 12407453.65 and a median of 13477500.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations sank 91.08% in 2022, then soared 121.36% in 2025.
- Over 5 years, Income from Continuing Operations stood at 7893073.0 in 2021, then tumbled by 91.08% to 15082000.0 in 2022, then grew by 12.72% to 13164000.0 in 2023, then surged by 30.22% to 9186000.0 in 2024, then jumped by 121.36% to 1962000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1962000.0, 8181000.0, and 14562000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | -87.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.96 Mn |
| Sep 30, 2025 | -8.18 Mn |
| Jun 30, 2025 | -14.56 Mn |
| Mar 31, 2025 | -16.21 Mn |
| Dec 31, 2024 | -9.19 Mn |
| Sep 30, 2024 | -9.63 Mn |
| Jun 30, 2024 | -15.67 Mn |
| Mar 31, 2024 | -18.81 Mn |
| Dec 31, 2023 | -13.16 Mn |
| Sep 30, 2023 | -12.13 Mn |
| Jun 30, 2023 | -13.66 Mn |
| Mar 31, 2023 | -13.71 Mn |
| Dec 31, 2022 | -15.08 Mn |
| Sep 30, 2022 | -11.16 Mn |
| Jun 30, 2022 | -13.30 Mn |
| Mar 31, 2022 | -14.33 Mn |
| Dec 31, 2021 | -7.89 Mn |
| Sep 30, 2021 | -14.30 Mn |
| Jun 30, 2021 | -10.30 Mn |
| Mar 31, 2021 | -18.83 Mn |